Combinatorial inhibition of MEK/ERK and γ-secretase increases efficacy in melanoma, papillary thyroid cancer, and CRC (Krepler et al., 2016, Yamashita et al., 2013, Schmidt et al., 2018). This evidence concerns the gene MAP2K7 and colorectal carcinoma.